glp-1 cardiovascular outcomes 2025 news Effects and Tolerability of Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Bridging the gap between GLP1-receptor

loss treatments

Prices could drop by 50 to 80 percent, making coverage restoration economically viable for even the most cost-conscious insurers

Marzook A, Tomas A, Jones B

Exenatide formulations show variable nausea rates: the twice-daily immediate-release preparation (Byetta) tends to produce higher rates of nausea (approximately 3050%), whilst the once-weekly extended-release formulation (Bydureon) demonstrates improved tolerability with nausea rates of approximately 1424%, according to their respective SmPCs

Yet little is known about what happens when therapy is discontinuedan increasingly important question as real-world discontinuation rates remain high